NCT07598214 Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
| NCT ID | NCT07598214 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Beni-Suef University |
| Condition | Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-02-03 |
| Primary Completion | 2026-11-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2025-02-03 with a primary completion date of 2026-11-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.
Eligibility Criteria
Inclusion Criteria: * Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy. Exclusion Criteria: * -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.
Contact & Investigator
marwa mohsen
PRINCIPAL INVESTIGATOR
clinical pharmacy department, Beni Suef University
Frequently Asked Questions
Who can join the NCT07598214 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07598214 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07598214 currently recruiting?
Yes, NCT07598214 is actively recruiting participants. Contact the research team at marwa.mohsen@pharm.bsu.edu.eg for enrollment information.
Where is the NCT07598214 trial being conducted?
This trial is being conducted at Banī Suwayf, Egypt.
Who is sponsoring the NCT07598214 clinical trial?
NCT07598214 is sponsored by Beni-Suef University. The principal investigator is marwa mohsen at clinical pharmacy department, Beni Suef University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.